Michelle Erwee, Takeda's Global Head of Access to Medicines, acknowledging the need for collective efforts, said "No single organization or group can fix all the problems that cause unequal access to medicines. As a leading biopharmaceutical company, we understand that we can help by making our medicines and vaccines more accessible to patients. This not only improves people's lives but is also essential to long- term sustainable business growth." The final session of the day showcased research and development programs, demonstrating commitment to address unmet medical needs and access to innovative therapies. Participants engaged in discussions, strategizing ways to fortify healthcare infrastructure, establish sustainable supply chains, and strengthen healthcare systems in resource-limited settings. In summary, day one confronted the complexities of regulatory frameworks and navigated the delicate balance between incentivizing innovation and ensuring affordable access to medicines.